A traditional Chinese medicine composition for preventing and treating rupture and bleeding of esophageal varices due to liver cirrhosis

Abstract

The invention discloses traditional Chinese medicine composition for preventing and treating cirrhosis esophageal variceal bleeding. The composition is prepared from traditional Chinese medicinal materials in parts by mass as follows: 30 parts of turtle carapaces, 30 parts of zedoray rhizomes, 30 parts of common burreed rhizomes, 30 parts of American ginseng, 20 parts of milkvetch roots, 30 parts of white peony roots, 20 parts of largehead atractylodes rhizomes, 20 parts of poria cocos, 10 parts of rhubarb, 1 part of musk and 15 parts of liquorice roots. The traditional Chinese medicine composition has functions of benefiting qi, promoting blood circulation, removing stasis and eliminating concretions, has significant curative effects on symptoms such as hepatalgia, jaundice, ascites, spider nevi, liver palms, tongue margin ecchymoses, splenomegaly and the like which are shown by cirrhosis esophageal varices, and has the effective rate higher than 95%, and a patient suffering from the cirrhosis esophageal variceal bleeding cannot bleed again after keeping taking the traditional Chinese medicine composition for treatment.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine products, and in particular relates to a traditional Chinese medicine composition for preventing and treating rupture and bleeding of esophageal varices due to liver cirrhosis. Background technique [0002] Hemorrhage of esophageal varices due to liver cirrhosis is one of the most common and serious complications in the decompensated stage of liver cirrhosis, with a mortality rate as high as 40% to 70%. Therefore, preventing the deterioration of liver cirrhosis and preventing bleeding from esophageal varices is very important to prolong the life of patients. At present, there are many clinical methods commonly used to prevent esophageal variceal bleeding due to liver cirrhosis, mainly including surgery, sclerotherapy, variceal ligation, and drugs to reduce portal pressure. However, most patients with liver cirrhosis and portal hypertension are not suitable for surgery or cannot tolerat...

AI Technical Summary

Problems solved by technology

However, most patients with liver cirrhosis and portal hypertension are not suitable for surgery or cannot tolerate surgery; sclerotherapy and varicose vein ligation have more adverse reactions; drug prevention is mostly carried out from the perspective of hemodynamics, including non-selective β receptor blockers, nitrate vasodilators and calcium channel blockers, etc. These drugs can slow down the occurrence of esophageal variceal bleeding to a certain extent, but have no obvious effect on liver cirrhosis itself that causes portal hypertension, and cannot Prevent the progression of hepatic fibrosis and the increase in intrahepatic and portosystemic vascular resistance caused by cirrhosis